drugset / Trial / NCT06994650

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

NCT06994650

Phase 3 Recruiting 140 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.

Timeline

Start
2025-08-13
Primary completion
2026-12
Completion
2027-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HRS9531 Unknown Subcutaneous